Unlimited Bio is thrilled to be among the Top 100 teams in the XPRIZE Healthspan contest, standing shoulder-to-shoulder with leading universities and public biotech companies.
Elite Academic Partners. Finalists include Brigham and Women’s Hospital (Harvard Medical School affiliate, $876 M NIH funding), University of Tokyo, Osaka University and Salk Institute, underscoring the world-class research in this cohort.
Publicly Traded Longevity Innovators. We join the ranks of GI Innovation (>$300 M raised), Longevity Innovator (LogIN) on the Tokyo Stock Exchange, Longeveron on U.S. markets, and now BioAge Labs, a California-based clinical-stage biotech pioneering therapies from human longevity datasets.
Unlimited Bio’s Edge: Launched in 2024 on a lean seed budget, we’ve already produced four gene-therapy constructs (VEGF, Follistatin, Klotho, BDNF) for an unprecedented multi-gene mouse trial kicking off in two weeks, demonstrating that speed and cost-efficiency can rival even the deepest-pocketed labs.
As we gear up for in vivo testing, this achievement spotlights Unlimited Bio’s ability to compete with billion-dollar institutions and public companies, proving that nimble innovation can lead the longevity revolution!
Elite Academic Partners. Finalists include Brigham and Women’s Hospital (Harvard Medical School affiliate, $876 M NIH funding), University of Tokyo, Osaka University and Salk Institute, underscoring the world-class research in this cohort.
Publicly Traded Longevity Innovators. We join the ranks of GI Innovation (>$300 M raised), Longevity Innovator (LogIN) on the Tokyo Stock Exchange, Longeveron on U.S. markets, and now BioAge Labs, a California-based clinical-stage biotech pioneering therapies from human longevity datasets.
Unlimited Bio’s Edge: Launched in 2024 on a lean seed budget, we’ve already produced four gene-therapy constructs (VEGF, Follistatin, Klotho, BDNF) for an unprecedented multi-gene mouse trial kicking off in two weeks, demonstrating that speed and cost-efficiency can rival even the deepest-pocketed labs.
As we gear up for in vivo testing, this achievement spotlights Unlimited Bio’s ability to compete with billion-dollar institutions and public companies, proving that nimble innovation can lead the longevity revolution!